Tarsus Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
TARS$70.84+3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and par value amounts)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $176,210 | $224,947 |
| Marketable securities | 140,742 | 2,495 |
| Accounts receivable, net | 29,159 | 16,621 |
| Inventory | 2,846 | 3,107 |
| Other receivables | 1,145 | 1,093 |
| Prepaid expenses | 7,015 | 7,868 |
| Total current assets | 357,117 | 256,131 |
| Inventory, non-current | 2,533 | — |
| Property and equipment, net | 2,393 | 1,468 |
| Intangible assets, net | 8,567 | 3,867 |
| Operating lease right-of-use assets | 1,802 | 1,880 |
| Long-term investments | 3,000 | 631 |
| Other assets | 888 | 1,514 |
| Total assets | $376,300 | $265,491 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and other accrued liabilities | $54,543 | $23,691 |
| Accrued payroll and benefits | 11,325 | 13,245 |
| Total current liabilities | 65,868 | 36,936 |
| Long-term debt, net | 71,708 | 29,819 |
| Other long-term liabilities | 1,240 | 1,748 |
| Total liabilities | 138,816 | 68,503 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 38,196,072 shares issued and outstanding at September 30, 2024 (unaudited); 34,211,190 shares issued and outstanding at December 31, 2023 | 6 | 5 |
| Additional paid-in capital | 574,229 | 441,641 |
| Accumulated other comprehensive gain (loss) | 346 | (2) |
| Accumulated deficit | (337,097) | (244,656) |
| Total stockholders’ equity | 237,484 | 196,988 |
| Total liabilities and stockholders’ equity | $376,300 | $265,491 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.